Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

George Lopez

Physician Assistant Bronx, NY Physician Assistant

NPI 1205972718 CMS profile 10770826

553 E Fordham Rd, Bronx, NY 10458

Open in the dashboard

General payments

$45,970

1,257 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Lopez of Bronx, NY is reported in the CMS Open Payments database as having received $45,970 across 1,257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,180 236
2024 General $13,124 314
2023 General $10,030 293
2022 General $4,988 207
2021 General $3,648 207

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Lopez
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to George Lopez were reported at $14,180. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year George Lopez Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,648 $132 $37–$438 $132
2022 $4,988 $155 $48–$522 $149
2023 $10,030 $167 $52–$557 $160
2024 $13,124 $178 $55–$600 $164
2025 $14,180 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Genzyme Corporation $14,991 64 payments
  2. Regeneron Healthcare Solutions, Inc. $9,413 95 payments
  3. AbbVie, Inc. $4,554 221 payments
  4. LEO Pharma Inc. $2,583 231 payments
  5. Dermavant Sciences, Inc. $2,188 72 payments
  6. Janssen Biotech, Inc. $1,731 68 payments
  7. UCB, Inc. $1,684 101 payments
  8. Lilly USA, LLC $1,232 52 payments
  9. Pfizer Inc. $1,230 67 payments
  10. Sun Pharmaceutical Industries Inc. $1,079 62 payments
  11. Other $5,286 224 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $23,547 1,218 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,781 15 payments
  3. Consulting Fee $2,084 3 payments
  4. Travel and Lodging $1,186 10 payments
  5. Honoraria $720 1 payment
  6. Education $653 10 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $17,086 89 payments
  2. DUPIXENT Inflammation And Immunology $7,416 80 payments
  3. VTAMA $2,330 75 payments
  4. ADBRY $2,300 200 payments
  5. DUPIXENT Immunology And Inflammation $1,969 13 payments
  6. SKYRIZI $1,853 93 payments
  7. TREMFYA $1,817 60 payments
  8. RINVOQ $1,733 83 payments
  9. Bimzelx $1,255 77 payments
  10. TALTZ $913 39 payments
  11. Other $11,120 636 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

914

Median for Physician Assistant: 241

Drug cost

$489,094

Median for Physician Assistant: $4,110

Branded share of claims

19.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 11 $142,550
Dupixent Pen Dupilumab Brand 37 $136,439
Opzelura Ruxolitinib Phosphate Brand 55 $105,989
Vtama Tapinarof Brand 19 $26,081
Eucrisa Crisaborole Brand 13 $17,904
Pimecrolimus Generic 46 $15,297
Tacrolimus Generic 44 $10,902
Clindamycin Phosphate Generic 51 $7,782
Clobetasol Propionate Generic 70 $5,081
Oxiconazole Nitrate Generic 12 $3,133

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$6,299 37 —
VTAMA
$1,802 19 —
TREMFYA
$732 — —
Bimzelx
$651 — —
ADBRY
$651 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record